Q-omics provides the consensus-scored DLX6 profile across patient tissues and cancer cell-line models. DLX6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DLX6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DLX6 RNA expression shows 14,748 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, and HNSC as cancer lineages where DLX6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLX6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLX6 survival associations across molecular data types. DLX6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLX6 RNA expression–survival associations across cancer types. High DLX6 expression shows unfavorable associations in KIRP, UVM, ESCA, ACC and MESO, but favorable associations in LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DLX6 RNA expression.
This table summarizes DLX6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DLX6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLX6 shows higher tumor expression in HNSC, KIRC, BLCA, LUSC, COAD and UCEC. The HNSC box plot shows higher DLX6 RNA expression in tumor versus normal tissue (log2 FC = +2.143, t-test p < 0.001).
This table shows molecular features associated with DLX6 in patient tissues and cancer cell lines. In patient samples, DLX6 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, DLX6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
